German body questions InterMune drug, shares drop

German body questions InterMune drug, shares drop

(Reuters) – Shares of InterMune Inc fell as much as 30 percent on Thursday, after a German advisory body raised questions on the clinical benefits of its lung drug Esbriet, raising concerns about reimbursement for the drug.